Nobivac Canine 1-DAPPv vaccine is a modified live virus vaccine for the vaccination of healthy dogs as an aid in the prevention of disease caused by canine distemper virus, canine adenovirus type 1 (hepatitis), canine parainfluenza virus, and canine parvovirus.
Shipping : Perishable
NOBIVAC Canine 1-DAPPv+L4 vaccine is a combination vaccine that unites the benefits of NOBIVAC Canine 1-DAPPv and NOBIVAC Lepto4 in one vaccination. One package of NOBIVAC Canine 1-DAPPv+L4 contains 25 doses. NOBIVAC Canine 1-DAPPv+L4 requires refrigeration and must be kept at refrigerator temperatures at all times. To ensure proper temperature, NOBIVAC Canine 1-DAPPv+L4 requires overnight shipping at an additional cost. Syringes are sold separately.
NOBIVAC® CANINE 1-DAPPv + L4
Intervet/Merck Animal Health
CANINE DISTEMPER-ADENOVIRUS TYPE 2-PARAINFLUENZA-PARVOVIRUS VACCINE Modified Live Virus LEPTOSPIRA CANICOLA-GRIPPOTYPHOSA-ICTEROHAEMORRHAGIAE-POMONA BACTERIN
FOR ANIMAL USE ONLY
IN THE ABSENCE OF A VETERINARIAN-CLIENT-PATIENT RELATIONSHIP, FEDERAL REGULATIONS PROHIBIT THE RELABELING, REPACKAGING, RESALE OR REDISTRIBUTION OF THE INDIVIDUAL CONTENTS OF THIS PACKAGE.
INDICATIONS: This product has been shown to be effective for vaccination of healthy dogs 8 weeks of age or older against canine distemper virus, canine adenovirus type 1 (hepatitis), canine parainfluenza virus, canine parvovirus, Leptospira canicola, L. icterohaemorrhagiae, L. pomona and L. grippotyphosa. Duration of Immunity has not been established. To review efficacy and safety data, go to productdata.aphis.usda.gov.
This product has also been shown to be effective against mortality and leptospiruria (shedding of Leptospira in the urine) caused by L. canicola, L. icterohaemorrhagiae, L. pomona and L. grippotyphosa. Data indicate the development of corneal opacity is not associated with the use of this product.
DOSAGE AND ADMINISTRATION: Shake the Nobivac Lepto4 vial and transfer its contents to the Nobivac Canine 1-DAPPv vial aseptically. Mix gently until dissolved. Inject one dose (1 mL) subcutaneously. The initial dose may be given at 8 weeks of age or older. Repeat dose 2 to 4 weeks later. Two doses are required for primary immunization.
The presence of maternal antibodies is known to interfere with the development of active immunity in dogs and additional boosters will be required in most young animals. Historically, annual revaccination has been recommended for this product. The need for this booster has not been established. For more information on revaccination frequency, in general or in the face of maternal antibody, consult your veterinarian or the manufacturer.
| Directions |
|
|---|
